Revakinagene taroretcel

瑞基塔锐赛

Report date: 2026/04/10 11:27:17

Base Information

Drug NameRevakinagene taroretcel
Drug Alias NameRexenusrevakinagene taroretcelrevakinagene taroretcel-lweyEncapsulated CNTFCiliary neurotrophic factor implant +[10] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Retinal pigment epithelial cell therapyCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionCiliary neurotrophic factor receptor gene transferenceNeurogenesis stimulants
TargetsCiliary neurotrophic factor receptor
Therapy Area/IndicationsMacular telangiectasia 2TelangiectasisGlaucoma +[7] 
Global Approved IndicationsMacular telangiectasia 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/03/05
Country/TerritoryUnited StatesAustraliaGermany +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGnt Pharma
China Registration ClassN/A

Develop Information

Active CompaniesGnt PharmaStanford University
Inactive CompaniesNational Eye Institute (Nei)
Active IndicationsMacular telangiectasia 2Glaucoma
Inactive IndicationsTelangiectasisRetinitis PigmentosaEye Diseases +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia